{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:44:00Z","timestamp":1789454640562,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jcpo.2023.100433","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T12:09:46Z","timestamp":1689595786000},"page":"100433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines"],"prefix":"10.1016","volume":"37","author":[{"given":"Suhib","family":"Fahmawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Shaughnessy Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghuang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jcpo.2023.100433_bib1","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1080\/10428194.2021.1953013","article-title":"Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study","volume":"62","author":"Al Hadidi","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.jcpo.2023.100433_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8161","article-title":"Enrollment of black participants in pivotal clinical trials supporting US food and drug administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"8","key":"10.1016\/j.jcpo.2023.100433_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2023.100433_bib4","article-title":"Partnering with all patients: ensuring shared decision making and evidence-based management for underrepresented groups with multiple myeloma","volume":"43","author":"Cerchione","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"8","key":"10.1016\/j.jcpo.2023.100433_bib5","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.jcpo.2023.100433_bib6","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/bloodadvances.2020004001","article-title":"Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study","volume":"5","author":"Fillmore","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.jcpo.2023.100433_bib7","unstructured":"The R Project for Statistical Computing, R: A Language and Environment for Statistical Computing, 2013. Accessed 8 March 2023. \u3008http:\/\/www.r-project.org\/\u3009."},{"issue":"25","key":"10.1016\/j.jcpo.2023.100433_bib8","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcpo.2023.100433_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","volume":"158","author":"Ailawadhi","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.jcpo.2023.100433_bib10","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.jcpo.2023.100433_bib11","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3324\/haematol.2022.281322","article-title":"Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma","volume":"107","author":"Asher","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jcpo.2023.100433_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/OP.21.00001","article-title":"Participation of black Americans in cancer clinical trials: current challenges and proposed solutions","volume":"17","author":"Awidi","year":"2021","journal-title":"JCO Oncol. Pract."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538323000504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538323000504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:08:01Z","timestamp":1761988081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538323000504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":12,"alternative-id":["S2213538323000504"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2023.100433","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2023.100433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100433"}}